Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2023 Filed Oct 30, 2023 20:55 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019858 · form4.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:52 UTC |
Bushman Julie LDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019856 · form4.xml · derivative · entry 6 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:52 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019856 · form4.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,673 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:50 UTC |
Vessey RupertDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019854 · form4.xml · derivative · entry 7 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:50 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019854 · form4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,885 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:49 UTC |
STEER RANDOLPH CDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019852 · form4.xml · derivative · entry 10 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/23) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:49 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019852 · form4.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,201 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:47 UTC |
HIGGINS JOHN LDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019850 · form4.xml · derivative · entry 11 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:47 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019850 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,608 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:42 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019848 · form4.xml · derivative · entry 8 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:42 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019848 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:40 UTC |
Nusse RoelandDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019846 · form4.xml · derivative · entry 10 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:40 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019846 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,497 Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:39 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019844 · form4.xml · derivative · entry 11 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:39 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019844 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,401 Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · derivative · entry 5 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $21.85 | $0.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · derivative · entry 4 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC |
Nusse RoelandDirector
|
SaleCommon Stock | 8,939 | $80.32 | $717,959.03 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · nonDerivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,872 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.09 to $80.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 16,000 | $22.95 | $367,200.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 16,000 | $21.85 | $349,600.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:19 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,100 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0001062993-23-017156 · form4.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,536 Underlying: Common Stock · 2,100 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:19 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 2,100 | $47.60 | $99,960.00 |
DisclosureSEC source: 0001062993-23-017156 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:24 UTC |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 45,923 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016717 · form4.xml · derivative · entry 19 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,923 Underlying: Common Stock · 45,923 shares Expires 2030-08-15 F10 · derivative.exercise_date: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/27, and options to purchase 11,480 shares vest on 8/15/2026. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:24 UTC |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 34,442 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016717 · form4.xml · derivative · entry 18 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,442 Underlying: Common Stock · 34,442 shares Expires 2030-08-15 F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:24 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 12,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016717 · form4.xml · derivative · entry 17 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,798 Underlying: Common Stock · 12,798 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:20 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 29,391 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016714 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,391 Underlying: Common Stock · 29,391 shares Expires 2030-08-15 F10 · derivative.exercise_date: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:20 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 22,043 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016714 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,043 Underlying: Common Stock · 22,043 shares Expires 2030-08-15 F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:20 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantRestricted Stock Units · Derivative | 8,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016714 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,191 Underlying: Common Stock · 8,191 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:17 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 15,904 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016712 · form4.xml · derivative · entry 5 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,904 Underlying: Common Stock · 15,904 shares Expires 2030-08-15 F5 · derivative.exercise_date: Options to purchase 3,976 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:17 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 11,928 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016712 · form4.xml · derivative · entry 4 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,928 Underlying: Common Stock · 11,928 shares Expires 2030-08-15 F4 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:17 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 4,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016712 · form4.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,432 Underlying: Common Stock · 4,432 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:14 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 59,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016707 · form4.xml · derivative · entry 18 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,095 Underlying: Common Stock · 59,095 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025. F9 · derivative.expiration_date: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:14 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 8,675 | $84.61 | $733,991.75 |
DisclosureSEC source: 0001062993-23-016707 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,269 F1 · balance_after: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:14 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 17,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016707 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,286,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:08 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 30,059 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016695 · form4.xml · derivative · entry 10 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,059 Underlying: Common Stock · 30,059 shares Expires 2030-08-15 F7 · derivative.exercise_date: Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:08 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 22,544 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016695 · form4.xml · derivative · entry 9 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,544 Underlying: Common Stock · 22,544 shares Expires 2030-08-15 F6 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:08 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 8,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016695 · form4.xml · derivative · entry 8 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,377 Underlying: Common Stock · 8,377 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F6 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 24, 2023 20:20 UTC Amendment |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 16,302 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-017082 · form4a.xml · derivative · entry 3 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,302 Underlying: Common Stock · 16,302 shares Expires 2030-08-15 F3 · shares: This grant was previously reported as options to purchase 15,904 shares. This amendment reflects the corrected number of stock options granted. F4 · derivative.exercise_date: Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027. Read SEC document |
| August 15, 2023 Filed Aug 24, 2023 20:20 UTC Amendment |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 148 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017082 · form4a.xml · derivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148 Underlying: Common Stock · 148 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 49 restricted stock units vest on each of 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025. F2 · derivative.expiration_date: 49 restricted stock units vest on each of 8/15/2024 and 8/15/2026, and 50 restricted stock units vest on 8/15/2025. Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:15 UTC Amendment |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 24,424 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022603 · form4a.xml · derivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,424 Underlying: Common Stock · 24,424 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:15 UTC Amendment |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 9,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022603 · form4a.xml · derivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,074 Underlying: Common Stock · 9,074 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:14 UTC Amendment |
Bohnen ShaneSVP - General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 12,924 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022602 · form4a.xml · derivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,924 Underlying: Common Stock · 12,924 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:14 UTC Amendment |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 4,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022602 · form4a.xml · derivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,802 Underlying: Common Stock · 4,802 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 23,881 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022601 · form4a.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,881 Underlying: Common Stock · 23,881 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment |
Kelderman KimPres. Diagnostics & Genom
|
GrantRestricted Stock Units · Derivative | 8,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022601 · form4a.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,873 Underlying: Common Stock · 8,873 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 37,314 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022600 · form4a.xml · derivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,314 Underlying: Common Stock · 37,314 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 13,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022600 · form4a.xml · derivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,865 Underlying: Common Stock · 13,865 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:13 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GiftCommon Stock | 9,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016265 · form4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,269,312 F1 · ownership.direct: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:31 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 51,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016040 · form4.xml · derivative · entry 12 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/5/2023, the Board of Directors certified vesting of 51,516 performance RSUs. F4 · derivative.expiration_date: On 8/5/2023, the Board of Directors certified vesting of 51,516 performance RSUs. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:31 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 31,962 | $82.17 | $2,626,317.54 |
DisclosureSEC source: 0001062993-23-016040 · form4.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,320 F1 · ownership.direct: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.